keyword
https://read.qxmd.com/read/38077389/potentiation-of-natural-killer-cells-to-overcome-cancer-resistance-to-nk-cell-based-therapy-and-to-enhance-antibody-based-immunotherapy
#1
REVIEW
Massimo Fantini, Philip Martin Arlen, Kwong Yok Tsang
Natural killer (NK) cells are cellular components of the innate immune system that can recognize and suppress the proliferation of cancer cells. NK cells can eliminate cancer cells through direct lysis, by secreting perforin and granzymes, or through antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC involves the binding of the Fc gamma receptor IIIa (CD16), present on NK cells, to the constant region of an antibody already bound to cancer cells. Cancer cells use several mechanisms to evade antitumor activity of NK cells, including the accumulation of inhibitory cytokines, recruitment and expansion of immune suppressor cells such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), modulation of ligands for NK cells receptors...
2023: Frontiers in Immunology
https://read.qxmd.com/read/37548440/igg-antibodies-mediated-gold-nanoparticles-conjugated-to-methotrexate-as-targeted-chemotherapy-for-lung-cancer
#2
JOURNAL ARTICLE
Asad Syed, Abu Baker, Mohamed Mohany, Abdallah M Elgorban, Mohd Sajid Khan, Salim S Al-Rejaie
Vincamine, a natural chemical, was used as a reducing agent in the synthesis of IgG antibodies mediated biogenic gold nanoparticles (IgGAuNPs). Eventually, the synthesised IgGAuNPs were bioconjugated with the chemotherapeutic drug methotrexate (MTX-IgGAuNPs). The IgG isotype can target cancer cells through polymorphic Fc gamma receptors (FcγRs) and have therapeutic effects. They can restrict cell division by inhibiting different intracellular signal transduction pathways and activating NK cells and macrophages through antibody-dependent cellular cytotoxicity and macrophage-mediated antibody-dependent phagocytosis, respectively...
December 2023: Artificial Cells, Nanomedicine, and Biotechnology
https://read.qxmd.com/read/37545491/egfr-selective-activation-of-cd27-co-stimulatory-signaling-by-a-bispecific-antibody-enhances-anti-tumor-activity-of-t-cells
#3
JOURNAL ARTICLE
Vinicio Melo, Levi Collin Nelemans, Martijn Vlaming, Harm Jan Lourens, Valerie R Wiersma, Vrouyr Bilemjian, Gerwin Huls, Marco de Bruyn, Edwin Bremer
A higher density of tumor infiltrating lymphocytes (TILs) in the tumor microenvironment, particularly cytotoxic CD8+ T cells, is associated with improved clinical outcome in various cancers. However, local inhibitory factors can suppress T cell activity and hinder anti-tumor immunity. Notably, TILs from various cancer types express the co-stimulatory Tumor Necrosis Factor receptor CD27, making it a potential target for co-stimulation and re-activation of tumor-infiltrated and tumor-reactive T cells. Anti-cancer therapeutics based on exploiting CD27-mediated T cell co-stimulation have proven safe, but clinical responses remain limited...
2023: Frontiers in Immunology
https://read.qxmd.com/read/36018829/full-length-recombinant-antibodies-from-escherichia-coli-production-characterization-effector-function-fc-engineering-and-clinical-evaluation
#4
REVIEW
Md Harunur Rashid
Although several antibody fragments and antibody fragment-fusion proteins produced in Escherichia coli ( E. coli ) are approved as therapeutics for various human diseases, a full-length monoclonal or a bispecific antibody produced in E. coli has not yet been approved. The past decade witnessed substantial progress in expression of full-length antibodies in the E. coli cytoplasm and periplasm, as well as in cell-free expression systems. The equivalency of E. coli -produced aglycosylated antibodies and their mammalian cell-produced counterparts, with respect to biochemical and biophysical properties, including antigen binding, in vitro and in vivo serum stability, pharmacokinetics, and in vivo serum half-life, has been demonstrated...
January 2022: MAbs
https://read.qxmd.com/read/35900183/impact-of-glycoengineering-and-anti-drug-antibodies-on-the-anti-cancer-activity-of-a-plant-made-lectin-fc-fusion-protein
#5
JOURNAL ARTICLE
Matthew Dent, Katarina L Mayer, Noel Verjan Garcia, Haixun Guo, Hiroyuki Kajiura, Kazuhito Fujiyama, Nobuyuki Matoba
Plants are an efficient production platform for manufacturing glycoengineered monoclonal antibodies and antibody-like molecules. Avaren-Fc (AvFc) is a lectin-Fc fusion protein or lectibody produced in Nicotiana benthamiana, which selectively recognizes cancer-associated high-mannose glycans. In this study, we report the generation of a glycovariant of AvFc that is devoid of plant glycans, including the core α1,3-fucose and β1,2-xylose residues. The successful removal of these glycans was confirmed by glycan analysis using HPLC...
July 28, 2022: Plant Biotechnology Journal
https://read.qxmd.com/read/35814459/relevance-of-fc-gamma-receptor-polymorphisms-in-cancer-therapy-with-monoclonal-antibodies
#6
REVIEW
Juan J Mata-Molanes, Joseba Rebollo-Liceaga, Elena Mª Martínez-Navarro, Ramón González Manzano, Antonio Brugarolas, Manel Juan, Manuel Sureda
Therapeutic monoclonal antibodies (mAbs), including immune checkpoint inhibitors (ICIs), are an important breakthrough for the treatment of cancer and have dramatically changed clinical outcomes in a wide variety of tumours. However, clinical response varies among patients receiving mAb-based treatment, so it is necessary to search for predictive biomarkers of response to identify the patients who will derive the greatest therapeutic benefit. The interaction of mAbs with Fc gamma receptors (FcγR) expressed by innate immune cells is essential for antibody-dependent cellular cytotoxicity (ADCC) and this binding is often critical for their in vivo efficacy...
2022: Frontiers in Oncology
https://read.qxmd.com/read/35397683/monoclonal-antibody-daratumumab-promotes-macrophage-mediated-anti-myeloma-phagocytic-activity-via-engaging-fc-gamma-receptor-and-activation-of-macrophages
#7
JOURNAL ARTICLE
Ying Gao, Lan Li, Yan Zheng, Weihua Zhang, Ben Niu, Yu Li
Daratumumab (DAR) is novel human anti-CD38 IgG1, high-affinity human monoclonal antibody having broad-spectrum killing activity. The antibody is recommended to treat multiple myeloma. Recently Antibody-dependent cellular phagocytosis (ADCP) have been identified as the potential mechanism of DAR in addition to complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). In the present study we evaluated the effect of Daratumumab on other effector cells of multiple myeloma...
August 2022: Molecular and Cellular Biochemistry
https://read.qxmd.com/read/34992090/role-of-fc%C3%AE-receptors-in-her2-targeted-breast-cancer-therapy
#8
REVIEW
Antonino Musolino, William J Gradishar, Hope S Rugo, Jeffrey L Nordstrom, Edwin P Rock, Fernanda Arnaldez, Mark D Pegram
Several therapeutic monoclonal antibodies (mAbs), including those targeting epidermal growth factor receptor, human epidermal growth factor receptor 2 (HER2), and CD20, mediate fragment crystallizable gamma receptor (FcγR)-dependent activities as part of their mechanism of action. These activities include induction of antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), which are innate immune mechanisms of cancer cell elimination. FcγRs are distinguished by their affinity for the Fc fragment, cell distribution, and type of immune response they induce...
January 2022: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/34719330/preclinical-characterization-of-bemarituzumab-an-anti-fgfr2b-antibody-for-the-treatment-of-cancer
#9
JOURNAL ARTICLE
Hong Xiang, Abigael G Chan, Ago Ahene, David I Bellovin, Rong Deng, Amy W Hsu, Ursula Jeffry, Servando Palencia, Janine Powers, James Zanghi, Helen Collins
Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibition of FGFR2b signaling and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). Bemarituzumab is being developed as a cancer therapeutic, and we summarize here the key nonclinical data that supported moving it into clinical trials. Bemarituzumab displayed sub-nanomolar cross-species affinity for FGFR2b receptors, with >20-fold enhanced binding affinity to human Fc gamma receptor IIIa compared with the fucosylated version...
January 2021: MAbs
https://read.qxmd.com/read/34244307/combinatorial-immunotherapy-of-n-803-il-15-superagonist-and-dinutuximab-with-ex-vivo-expanded-natural-killer-cells-significantly-enhances-in-vitro-cytotoxicity-against-gd2-pediatric-solid-tumors-and-in-vivo-survival-of-xenografted-immunodeficient-nsg-mice
#10
JOURNAL ARTICLE
Yaya Chu, Gaurav Nayyar, Susiyan Jiang, Jeremy M Rosenblum, Patrick Soon-Shiong, Jeffrey T Safrit, Dean A Lee, Mitchell S Cairo
BACKGROUND: Children with recurrent and/or metastatic osteosarcoma (OS), neuroblastoma (NB) and glioblastoma multiforme (GBM) have a dismal event-free survival (<25%). The majority of these solid tumors highly express GD2. Dinutuximab, an anti-GD2 monoclonal antibody, significantly improved event-free survival in children with GD2+ NB post autologous stem cell transplantation and enhanced natural killer (NK) cell-mediated antibody-dependent cell cytotoxicity. Thus, approaches to increase NK cell number and activity, improve persistence and trafficking, and enhance tumor targeting may further improve the clinical benefit of dinutuximab...
July 2021: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/34049929/g-csf-as-a-suitable-alternative-to-gm-csf-to-boost-dinutuximab-mediated-neutrophil-cytotoxicity-in-neuroblastoma-treatment
#11
COMPARATIVE STUDY
Paula Martinez Sanz, Dieke J van Rees, Lieke M J van Zogchel, Bart Klein, Panagiota Bouti, Hugo Olsman, Karin Schornagel, Ivana Kok, Ali Sunak, Kira Leeuwenburg, Ilse Timmerman, Miranda P Dierselhuis, Waleed M Kholosy, Jan J Molenaar, Robin van Bruggen, Timo K van den Berg, Taco W Kuijpers, Hanke L Matlung, Godelieve A M Tytgat, Katka Franke
BACKGROUND: Current immunotherapy for patients with high-risk neuroblastoma involves the therapeutic antibody dinutuximab that targets GD2, a ganglioside expressed on the majority of neuroblastoma tumors. Opsonized tumor cells are killed through antibody-dependent cellular cytotoxicity (ADCC), a process mediated by various immune cells, including neutrophils. The capacity of neutrophils to kill dinutuximab-opsonized tumor cells can be further enhanced by granulocyte-macrophage colony-stimulating factor (GM-CSF), which has been shown in the past to improve responses to anti-GD2 immunotherapy...
May 2021: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/33212886/fc-engineering-for-modulated-effector-functions-improving-antibodies-for-cancer-treatment
#12
REVIEW
Rena Liu, Robert J Oldham, Emma Teal, Stephen A Beers, Mark S Cragg
The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage innate immune effectors through interactions mediated by their fragment crystallizable (Fc) domain. By delivering Fc-Fc gamma receptor (FcγR) and Fc-C1q interactions, mAb are able to link exquisite specificity to powerful cellular and complement-mediated effector functions. Fc interactions can also facilitate enhanced target clustering to evoke potent receptor signaling. These observations have driven decades-long research to delineate the properties within the Fc that elicit these various activities, identifying key amino acid residues and elucidating the important role of glycosylation...
November 17, 2020: Antibodies
https://read.qxmd.com/read/32620047/anti-cd20-rituximab-igg1-igg3-and-igg4-but-not-igg2-subclass-trigger-ca-2-mobilization-and-cytotoxicity-in-human-nk-cells
#13
JOURNAL ARTICLE
Marta Freitas Monteiro, Maria Papaserafeim, Aline Réal, Gisella L Puga Yung, Jörg D Seebach
NK cell-mediated Ab-dependent cellular cytotoxicity (ADCC) is increasingly recognized to play an important role in cancer immunotherapy, transplant rejection, and autoimmunity. However, several aspects of the molecular interactions of IgG subclasses with the Fc-gamma receptor IIIA (FcγRIIIA)/CD16a expressed on NK cells remain unknown. The aim of the current study was to further analyze the role of IgG subclasses and FCGR3A V158F single nucleotide polymorphism (SNP) on Ca2+ signaling and NK cell-mediated ADCC against Daudi target cells in vitro...
October 2020: Journal of Leukocyte Biology
https://read.qxmd.com/read/32106752/hx008-a-humanized-pd-1-blocking-antibody-with-potent-antitumor-activity-and-superior-pharmacologic-properties
#14
JOURNAL ARTICLE
Jibin Zhang, Ying Huang, Gan Xi, Faming Zhang
Through reactivating tumor-infiltrating lymphocytes, therapeutics targeting programmed cell death protein 1 (PD-1) demonstrate impressive clinical efficacy in the treatment of multiple cancers. In this report, we characterize HX008, a humanized IgG4S228P anti-PD-1 monoclonal antibody with an engineered Fc domain, in a series of in vitro assays and in vivo studies. In vitro , HX008 binds to human PD-1 with high affinity and potently suppresses the interaction of PD-1 with PD-L1 and PD-L2. The lack of detectable binding to complement C1q and Fc gamma receptor III-a (FcγRIIIa) suggested that HX008 maintained reduced antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity...
January 2020: MAbs
https://read.qxmd.com/read/31940587/histone-deacetylase-inhibitors-valproic-acid-and-vorinostat-enhance-trastuzumab-mediated-antibody-dependent-cell-mediated-phagocytosis
#15
JOURNAL ARTICLE
Johannes Laengle, Julijan Kabiljo, Leah Hunter, Jakob Homola, Sophie Prodinger, Gerda Egger, Michael Bergmann
BACKGROUND: The monoclonal antibody (mAb) trastuzumab is part of the standard of care for patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. Antibody-dependent cell-mediated phagocytosis (ADCP) and cytotoxicity (ADCC) are major mechanisms of action of the mAb trastuzumab. Histone deacetylase inhibitors (HDACi), such as valproic acid (VPA) or vorinostat (SAHA), exert several immunostimulatory properties, which contribute at least in part to their anticancer effect...
January 2020: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/31735912/boosting-therapeutic-potency-of-antibodies-by-taming-fc-domain-functions
#16
REVIEW
Tae Hyun Kang, Sang Taek Jung
Monoclonal antibodies (mAbs) are one of the most widely used drug platforms for infectious diseases or cancer therapeutics because they selectively target pathogens, infectious cells, cancerous cells, and even immune cells. In this way, they mediate the elimination of target molecules and cells with fewer side effects than other therapeutic modalities. In particular, cancer therapeutic mAbs can recognize cell-surface proteins on target cells and then kill the targeted cells by multiple mechanisms that are dependent upon a fragment crystallizable (Fc) domain interacting with effector Fc gamma receptors, including antibody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated phagocytosis...
November 18, 2019: Experimental & Molecular Medicine
https://read.qxmd.com/read/29239690/antibody-drug-conjugates-design-and-development-for-therapy-and-imaging-in-and-beyond-cancer-labex-mabimprove-industrial-workshop-july-27-28-2017-tours-france
#17
Camille Martin, Claire Kizlik-Masson, André Pèlegrin, Hervé Watier, Marie-Claude Viaud-Massuard, Nicolas Joubert
The annual "Antibody Industrial Symposium", co organized by LabEx MAbImprove, MabDesign and Polepharma, was held in Tours, France on June 27-28, 2017. The focus was on antibody-drug-conjugates (ADCs), new entities which realize the hope of Paul Ehrlich's magic bullet. ADCs result from the bioconjugation of a highly cytotoxic drug to a selective monoclonal antibody, which acts as a vector. Building on knowledge gained during the development of three approved ADCs, brentuximab vedotin (Adcetris®), ado trastuzumab emtansine (Kadcyla®) and inotuzumab ozogamicin (Besponsa®), and the many ADCs in development, this meeting addressed strategies and the latest innovations in the field from fundamental research to manufacturing...
February 2018: MAbs
https://read.qxmd.com/read/28542406/human-igg3-with-extended-half-life-does-not-improve-fc-gamma-receptor-mediated-cancer-antibody-therapies-in-mice
#18
JOURNAL ARTICLE
Rens Braster, Simran Grewal, Remco Visser, Helga K Einarsdottir, Marjolein van Egmond, Gestur Vidarsson, Marijn Bögels
BACKGROUND: Current anti-cancer therapeutic antibodies that are used in the clinic are predominantly humanized or fully human immunoglobulin G1 (IgG1). These antibodies bind with high affinity to the target antigen and are efficient in activating the immune system via IgG Fc receptors and/or complement. In addition to IgG1, three more isotypes are present in humans, of which IgG3 has been found to be superior compared to human IgG1 in inducing antibody dependent cell cytotoxicity (ADCC), phagocytosis or activation of complement in some models...
2017: PloS One
https://read.qxmd.com/read/27712994/identification-of-high-affinity-anti-cd16a-allotype-independent-human-antibody-domains
#19
JOURNAL ARTICLE
Wei Li, Hongjia Yang, Dimiter S Dimitrov
CD16A (FcγRIIIA) is an activating receptor mostly expressed on natural killer (NK) cells and monocytes/macrophages. It can mediate antibody-dependent cell-mediated cytotoxicity (ADCC) through low-affinity interaction with human immunoglobulin G (IgG) Fc. It can also mediate cell lysis if NK cells are guided by bispecific killer cells engagers (BiKEs). BiKEs showed some success in clinical trials of cancer and are promising candidate therapeutics. However, currently reported BiKEs are based on antibody fragments (scFvs) of relatively large size...
October 2016: Experimental and Molecular Pathology
https://read.qxmd.com/read/27004307/correlation-of-fc%C3%AE-riiia-polymorphisms-to-the-response-of-rituximab-in-thai-patients-with-diffuse-large-b-cell-lymphoma
#20
JOURNAL ARTICLE
Naruemol Angsirisak, Supeecha Wittayalertpanya, Wacharee Limpanasithikul, Udomsak Bunworasate, Danai Owattanapanich
BACKGROUND: Rituximab is an anti-CD20 chimeric antibody widely used in combination with CHOP regimen for the treatment of diffuse large B-cell lymphoma (DLBCL). It is suggested that this antibody destroys B lymphoma cells mainly by antibody dependent cellular cytotoxicity (ADCC) mechanism via the binding of the drug to FC gamma IIIa receptor (FcγRIIIa) on natural killer (NK) cells, affected to kill cancer cells. The FcγRIIIa has genetic polymorphism at nucleotide position 559 (G559T or V158F or rs396991) have shown influence on the binding and efficacy of rituximab...
December 2015: Journal of the Medical Association of Thailand
keyword
keyword
92117
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.